The former Genzyme CEO and chairman has joined the biotech Prosensa as a strategic adviser, bringing his experience in building Genzyme into a world leader in rare diseases.
Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report . This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.
Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.
There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >> Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>
AVI Biopharma heralded the news that its lead therapy hit the primary endpoint in a Phase IIb study, increasing levels of dystrophin in a tiny trial for Duchenne muscular dystrophy, but the boys did not experience a significant improvement in walking ability,
The Dutch biotech Prosensa has rounded up 23 million euros--about $30 million--in a new round earmarked to back its work on RNA drug development for Duchenne muscular dystrophy and other rare
GlaxoSmithKline has committed up to $680 in upfront fees and milestones to team with the Dutch biotech Prosensa on a package of four RNA programs aimed at Duchenne Muscular Dystrophy. Glaxo gets the